Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of $1.90, $0.36 better than the analyst estimate of $1.54. Revenue for the quarter came in at $658.4 million versus the consensus estimate of $589.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.